JDHIF:OTC-JD Health International Inc (USD)

COMMON STOCK | Medical Care Facilities |

Last Closing

USD 3.65

Change

0.00 (0.00)%

Market Cap

USD 11.64B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-15 )

Largest Industry Peers for Medical Care Facilities

Symbol Name Price(Change) Market Cap
FSNUY Fresenius SE & Co KGaA ADR

+0.22 (+2.91%)

USD 17.80B
FSNUF Fresenius SE & Co. KGaA

N/A

USD 17.32B
FMCQF Fresenius Medical Care AG & Co..

N/A

USD 13.85B
BDULF Bangkok Dusit Medical Services..

N/A

USD 13.23B
JDHIY JD Health International Inc

N/A

USD 13.08B
BDUUY Bangkok Dusit Medical Services..

N/A

USD 12.69B
BDUUF Bangkok Dusit Medical Services..

N/A

USD 12.31B
IHHHF IHH Healthcare Berhad

N/A

USD 11.26B
RMYHY Ramsay Health Care Ltd ADR

N/A

USD 7.87B
RMSYF Ramsay Health Care Limited

+1.32 (+4.00%)

USD 7.58B

ETFs Containing JDHIF

KEMQ KraneShares Emerging Mark.. 0.00 % 0.80 %

-0.04 (0.73%)

USD 0.02B
HSTC:LSE HSBC Hang Seng Tech UCITS.. 0.00 % 0.00 %

+0.01 (+0.73%)

USD 2.71B
HSTE:LSE HSBC Hang Seng Tech UCITS.. 0.00 % 0.00 %

+0.04 (+0.73%)

USD 2.68B

Market Performance

  Market Performance vs. Industry/Classification (Medical Care Facilities) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -27.00% 30% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.00% 27% F 22% F
Trailing 12 Months  
Capital Gain -42.16% 35% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.16% 33% F 26% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -18.25% 32% F 14% F
Dividend Return -18.25% 32% F 14% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 33.00% 68% D+ 67% D+
Risk Adjusted Return -55.31% 28% F 13% F
Market Capitalization 11.64B 90% A- 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.